Arsenical Keratosis Follow-up
- Author: from Memorial Sloan-Kettering - Chih-Shan Jason Chen, MD, PhD; Chief Editor: Dirk M Elston, MD more...
Further Outpatient Care
Regular skin surveillance and physical examination are necessary for patients who present with cutaneous lesions of chronic arsenicalism because aggressive squamous cell carcinoma may evolve de novo or from existing arsenical keratoses or Bowen disease.
Deterrence/Prevention
Educate patients on early detection and avoidance of arsenic exposure. Identify possible exposure sources in the environment (eg, arsenic-contaminated drinking water, plywood containing arsenic). Advise patients to avoid taking herbal medicine with uncertain arsenic content. Evidence suggests smoking may have additional effect on arsenic induced skin lesions. Smoke cessation and sun protection may modify the damage of arsenic toxicity.[7]
Complications
Arsenical keratosis occasionally evolves into carcinoma after a number of years. Bowen disease is the most common form of skin cancer induced by arsenic exposure. Arsenical squamous cell carcinoma occurs less frequently than Bowen disease, but it appears to be more aggressive than sun-induced squamous cell carcinoma. Previous reports have shown a much higher incidence of fatal metastases among patients with arsenical squamous cell carcinoma.
A variety of internal cancers due to arsenic ingestion have been reported. The presence of arsenic-induced cutaneous Bowen disease has been viewed as a cutaneous marker of possible internal malignancy, but this issue is still controversial.
Prognosis
Arsenical keratosis is not a fatal disease, but it may persist indefinitely and can become bothersome over time because of pain, bleeding, fissuring, and ulceration.
A dose-response relationship exists between arsenic exposure and health effects. Exposure to higher concentrations of arsenic and a longer duration of exposure to arsenic may increase the risk of invasive skin cancers and internal malignancies, which may result in fatality.[34]
Patient Education
For patient education material, visit eMedicine's Cancer and Tumors Center, as well as Skin Cancer and Skin Biopsy.
Tapio S, Grosche B. Arsenic in the aetiology of cancer. Mutat Res. Jun 2006;612(3):215-46. [Medline].
Hartwig A, Groblinghoff UD, Beyersmann D, Natarajan AT, Filon R, Mullenders LH. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis. Feb 1997;18(2):399-405. [Medline].
Jha AN, Noditi M, Nilsson R, Natarajan AT. Genotoxic effects of sodium arsenite on human cells. Mutat Res. Dec 16 1992;284(2):215-21. [Medline].
Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A. Sep 30 1997;94(20):10907-12. [Medline].
Kachinskas DJ, Phillips MA, Qin Q, Stokes JD, Rice RH. Arsenate perturbation of human keratinocyte differentiation. Cell Growth Differ. Nov 1994;5(11):1235-41. [Medline].
Germolec DR, Yoshida T, Gaido K, et al. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol. Nov 1996;141(1):308-18. [Medline].
Chen Y, Parvez F, Gamble M, Islam T, Ahmed A, Argos M. Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol Appl Pharmacol. Sep 1 2009;239(2):184-92. [Medline].
Ghosh P, Banerjee M, Giri AK, Ray K. Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res. Sep-Oct 2008;659(3):293-301. [Medline].
Banerjee M, Sarma N, Biswas R, Roy J, Mukherjee A, Giri AK. DNA repair deficiency leads to susceptibility to develop arsenic-induced premalignant skin lesions. Int J Cancer. Jul 15 2008;123(2):283-7. [Medline].
Mandal BK, Suzuki KT. Arsenic round the world: a review. Talanta. Aug 16 2002;58(1):201-35. [Medline].
Tollestrup K, Frost FJ, Cristiani M, McMillan GP, Calderon RL, Padilla RS. Arsenic-induced skin conditions identified in southwest dermatology practices: an epidemiologic tool?. Environ Geochem Health. Feb 2005;27(1):47-53. [Medline].
Barati AH, Maleki A, Alasvand M. Multi-trace elements level in drinking water and the prevalence of multi-chronic arsenical poisoning in residents in the west area of Iran. Sci Total Environ. Mar 1 2010;408(7):1523-9. [Medline].
Yeh S, How SW, Lin CS. Arsenical cancer of skin. Histologic study with special reference to Bowen's disease. Cancer. Feb 1968;21(2):312-39. [Medline].
Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst. Mar 1968;40(3):453-63. [Medline].
Fierz U. [Follow-up studies of the side-effects of the treatment of skin diseases with inorganic arsenic]. Dermatologica. 1965;131(1):41-58. [Medline].
Rahman MM, Chowdhury UK, Mukherjee SC, et al. Chronic arsenic toxicity in Bangladesh and West Bengal, India--a review and commentary. J Toxicol Clin Toxicol. 2001;39(7):683-700. [Medline].
Tondel M, Rahman M, Magnuson A, Chowdhury IA, Faruquee MH, Ahmad SA. The relationship of arsenic levels in drinking water and the prevalence rate of skin lesions in Bangladesh. Environ Health Perspect. Sep 1999;107(9):727-9. [Medline].
Haque R, Mazumder DN, Samanta S, et al. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. Epidemiology. Mar 2003;14(2):174-82. [Medline].
Miki Y, Kawatsu T, Matsuda K, Machino H, Kubo K. Cutaneous and pulmonary cancers associated with Bowen's disease. J Am Acad Dermatol. Jan 1982;6(1):26-31. [Medline].
Lien HC, Tsai TF, Lee YY, Hsiao CH. Merkel cell carcinoma and chronic arsenicism. J Am Acad Dermatol. Oct 1999;41(4):641-3. [Medline].
Smith AH, Steinmaus CM. Health effects of arsenic and chromium in drinking water: recent human findings. Annu Rev Public Health. Apr 29 2009;30:107-22. [Medline].
Tay CH. Cutaneous manifestations of arsenic poisoning due to certain Chinese herbal medicine. Australas J Dermatol. Dec 1974;15(3):121-31. [Medline].
Tay CH, Seah CS. Arsenic poisoning from anti-asthmatic herbal preparations. Med J Aust. Sep 13 1975;2(11):424-8. [Medline].
Chi YW, Chen SL, Yang MH, et al. [Heavy metals in traditional Chinese medicine: ba-pao-neu-hwang-san]. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. May-Jun 1993;34(3):181-90. [Medline].
Guha Mazumder DN. Chronic arsenic toxicity: clinical features, epidemiology, and treatment: experience in West Bengal. J Environ Sci Health A Tox Hazard Subst Environ Eng. Jan 2003;38(1):141-63. [Medline].
Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect. Jul 2000;108(7):655-61. [Medline].
Yoshida T, Yamauchi H, Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol. Aug 1 2004;198(3):243-52. [Medline].
WashingtonDeceit. Dermatopathology of arsenical keratosis. YouTube. Available at www.youtube.com/watch?v=xBreXMMHmLU. Accessed February 26, 2008.
Son SB, Song HJ, Son SW. Successful treatment of palmoplantar arsenical keratosis with a combination of keratolytics and low-dose acitretin. Clin Exp Dermatol. Mar 2008;33(2):202-4. [Medline].
Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen's disease with acitretin. Int J Dermatol. Feb 2002;41(2):84-7. [Medline].
Sharma SC, Simpson NB. Treatment of arsenical keratosis with etretinate. Acta Derm Venereol. 1983;63(5):449-52. [Medline].
Boonchai W. Treatment of precancerous and cancerous lesions of chronic arsenicism with 5% imiquimod cream. Arch Dermatol. Apr 2006;142(4):531-2. [Medline].
Hsueh YM, Cheng GS, Wu MM, Yu HS, Kuo TL, Chen CJ. Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br J Cancer. Jan 1995;71(1):109-14. [Medline].
Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol. Mar 1989;8(2):99-104. [Medline].
Merck Pharmaceuticals. Merck's Manual of the Materia Medica. ed. Whitehouse Station, NJ: 1899.

